View Financial HealthTdspharm 配当と自社株買い配当金 基準チェック /06Tdspharm配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,600, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 58% over the past year.Valuation Update With 7 Day Price Move • Jun 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,910, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 47% over the past year.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩7,010, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 38% over the past year.New Risk • Mar 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 60% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₩50.1b market cap, or US$33.3m).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,500, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.お知らせ • Feb 10Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Jan 29Risks To Shareholder Returns Are Elevated At These Prices For Tdspharm Co., Ltd. (KOSDAQ:464280)With a price-to-earnings (or "P/E") ratio of 16.8x Tdspharm Co., Ltd. ( KOSDAQ:464280 ) may be sending bearish signals...New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩58.1b market cap, or US$39.5m).Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,500, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.分析記事 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...Buy Or Sell Opportunity • Jul 30Now 22% overvaluedOver the last 90 days, the stock has fallen 9.9% to ₩11,000. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.Buy Or Sell Opportunity • Jul 15Now 25% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₩11,270. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.お知らせ • Feb 08Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Sep 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩120.8b (US$90.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (₩120.8b market cap, or US$90.4m).決済の安定と成長配当データの取得安定した配当: A464280の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A464280の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Tdspharm 配当利回り対市場A464280 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A464280)n/a市場下位25% (KR)1.5%市場トップ25% (KR)4.5%業界平均 (Pharmaceuticals)1.2%アナリスト予想 (A464280) (最長3年)n/a注目すべき配当: A464280は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A464280は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A464280の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A464280が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/01 23:23終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tdspharm Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,600, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 9x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 58% over the past year.
Valuation Update With 7 Day Price Move • Jun 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,910, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 47% over the past year.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩7,010, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 38% over the past year.
New Risk • Mar 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 60% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₩50.1b market cap, or US$33.3m).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,500, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.
お知らせ • Feb 10Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Jan 29Risks To Shareholder Returns Are Elevated At These Prices For Tdspharm Co., Ltd. (KOSDAQ:464280)With a price-to-earnings (or "P/E") ratio of 16.8x Tdspharm Co., Ltd. ( KOSDAQ:464280 ) may be sending bearish signals...
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩58.1b market cap, or US$39.5m).
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,500, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.
分析記事 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...
Buy Or Sell Opportunity • Jul 30Now 22% overvaluedOver the last 90 days, the stock has fallen 9.9% to ₩11,000. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.
Buy Or Sell Opportunity • Jul 15Now 25% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₩11,270. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.
お知らせ • Feb 08Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Sep 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩120.8b (US$90.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (₩120.8b market cap, or US$90.4m).